Quick Answer ADAMANT DRI PROCESSING & MINERALS GROUP reported Total Revenue of $48.7 thousand for fiscal year 2018. ADAMANT DRI PROCESSING & MINERALS GROUP — Key Financials by Year Metric 2021 2020 2019 2018 2017 2016 Total Revenue — — — $48.7K-97.2% $1.76M+186.3% $613.3K-14.9% Revenue (ASC 606) — — — $48.7K+4745.8% $1.0K — Net Income … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Gross Profit of $292.76 million for fiscal year 2025. ADMA BIOLOGICS, INC. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2025 $292.76M +33.3% 2024 $219.55M +146.8% 2023 $88.94M +152.2% 2022 $35.27M +2906.4% 2021 $1.17M +106.2% 2020 -$19.07M -4347.0% 2012 $449.1K -18.9% 2011 $553.5K — Quarterly Gross … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Operating Income of $191.44 million for fiscal year 2025. ADMA BIOLOGICS, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $191.44M +37.7% 2024 $138.98M +542.5% 2023 $21.63M +155.0% 2022 -$39.37M +32.6% 2021 -$58.37M +10.1% 2020 -$64.91M -56.7% 2019 -$41.42M +31.3% 2018 -$60.29M -53.4% 2017 -$39.31M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported R&D Expense of $4.76 million for fiscal year 2025. ADMA BIOLOGICS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $4.76M +162.7% 2024 $1.81M -45.1% 2023 $3.30M -8.7% 2022 $3.61M -0.9% 2021 $3.65M -38.3% 2020 $5.91M +152.0% 2019 $2.34M +134.4% 2019 $1.00M -74.5% 2018 $3.93M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Stockholders Equity of $477.32 million for fiscal year 2025. ADMA BIOLOGICS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $477.32M +36.8% 2024 $349.02M +158.1% 2023 $135.21M -11.0% 2022 $151.97M +7.7% 2021 $141.17M +60.0% 2020 $88.25M +236.9% 2019 $26.19M +32.5% 2018 $19.77M -51.0% 2017 $40.33M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Long-Term Debt of $69.33 million for fiscal year 2025. ADMA BIOLOGICS, INC. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $69.33M -4.2% 2024 $72.34M — 2019 $0.00 -100.0% 2018 $2.76M +0.0% 2017 $2.76M +54.2% 2016 $1.79M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Cash and Equivalents of $87.63 million for fiscal year 2025. ADMA BIOLOGICS, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $87.63M -15.0% 2024 $103.15M +100.9% 2023 $51.35M -40.6% 2022 $86.52M +69.4% 2021 $51.09M -8.6% 2020 $55.92M +109.0% 2019 $26.75M -0.0% 2018 $26.75M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Total Assets of $624.24 million for fiscal year 2025. ADMA BIOLOGICS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $624.24M +27.7% 2024 $488.68M +48.5% 2023 $329.18M -5.5% 2022 $348.46M +26.1% 2021 $276.25M +33.0% 2020 $207.67M +63.4% 2019 $127.09M +43.0% 2018 $88.88M -17.7% 2017 $108.02M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Net Income of $146.93 million for fiscal year 2025. ADMA BIOLOGICS, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $146.93M -25.7% 2024 $197.67M +800.0% 2023 -$28.24M +57.2% 2022 -$65.90M +8.0% 2021 -$71.65M +5.4% 2020 -$75.75M -56.9% 2019 -$48.28M +26.6% 2018 -$65.74M -50.2% 2017 -$43.76M … Read more
Quick Answer ADMA BIOLOGICS, INC. reported Diluted EPS of $0.60 per share for fiscal year 2025. ADMA BIOLOGICS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $0.60 -25.9% 2024 $0.81 +723.1% 2023 -$0.13 +60.6% 2022 -$0.33 +35.3% 2021 -$0.51 +42.0% 2020 -$0.88 — Quarterly Diluted EPS Quarter Ending Diluted EPS … Read more